David D. Chism
101 works · 8,023 citations · h-index 25
Top works
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
- Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
- Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association
- IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK
- Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma
- Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia
- Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.
- Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
- Peroxisome proliferator-activated receptor γ and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias
- First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
- Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
- Targeting Survivin Expression Induces Cell Proliferation Defect and SubsequentCell Death Involving Mitochondrial Pathway in Myeloid Leukemic Cells
- A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance
- Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
- Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19